- Poster presentation
- Open Access
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
© Wendig et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Total Cholesterol
- Triglyceride Level
To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosamprenavir (FOSAQ) in HIV-positive patients, treated without reverse transcriptase inhibitors (RTI).
Comparative cohort analysis on 173 patients receiving LOPSAQ, ATSAQ or FOSAQ as only antiretroviral therapy (ART). Total cholesterol and triglycerides were measured at baseline (BL) and in the course over 48 weeks after initiation of a ritonavir-boosted double PI regimen. High-density-lipoprotein (HDL) and low-density-lipoprotein (LDL) were measured after an overnight fast.
After 48 weeks on a double-boosted PI regimen, all three patient groups showed significant increases in total cholesterol. The increase in triglyceride levels was only significant for LOPSAQ, but not for ATSAQ or FOSAQ. Overall, <5% required a new LLA-therapy during the first 48 weeks. HDL- and LDL-cholesterol increases were not significant. The cardiovascular impact of these lipometabolic interferences requires further investigations.
This article is published under license to BioMed Central Ltd.